Skip to main content
. 2022 Nov 11;13:1034253. doi: 10.3389/fimmu.2022.1034253

Figure 3.

Figure 3

The pooled CR (A) and ORR (B) in patients with R/R indolent B-NHL receiving copanlisib monotherapy were significantly lower than those receiving combination therapy, including copanlisib plus rituximab, while result for pooled SDR (C) was reversed between the two groups.